It’s not going to reach those levels until release of blinded trial results. EIND patients are viewed as anecdotal by the FDA. It’s coming, be patient.
This is a small biotech trying to become relevant in the world of Big Pharma. It’s not easy to do and only strong blinded results will move it to the spotlight.
As far as money, to say NP has failed is totally unfair. Most if not all of the grants to date have gone to vaccines not treatments. NP has done a good job of keeping dilution to a minimum. This is extremely difficult to do for a pre revenue company.
Unless you have inside information, it’s impossible to know what partnership conversations are on going. They certainly are not going to rip their hand.
It’s so easy to be a Monday morning quarterback. Running a billion dollar company is not easy. Running one that’s pre revenue is even more difficult.
IMO, we need to sit back, wait for the mild to moderate trial to be unblinded (estimated to be in approx 30 days) and let’s see what the FDA does with it. I expect we will get approval quickly thereafter and national media will follow. Just my two cents.
News 
Market Data 
Discover 
